

non-human host transformed by a recombinant DNA molecule  
[characterized by] comprising a DNA sequence selected from the  
group consisting of:

(a) DNA sequences which hybridize to any of the DNA  
inserts of G-pBR322(Pst)/HFIF1, G-pBR322(Pst)/HFIF3  
(DSM 1791), G-pBR322(Pst)/HFIF6 (DSM 1792), and  
G-pBR322(Pst)/HFIF7 (DSM 1793), and which code for a  
polypeptide displaying antiviral activity, and  
(b) DNA sequences which are degenerate as a result of  
the genetic code to the DNA sequences defined in (a);  
said DNA sequence being operatively linked to an expression  
control sequence in the recombinant DNA molecule; and

2) a pharmaceutically acceptable carrier.

REMARKS

Applicant has amended claim 31 to clarify that the  
claimed composition comprises a polypeptide produced by a non-  
human host and a pharmaceutically acceptable carrier, and to  
recite more specifically what applicant regards as his  
invention. Applicant has also amended claim 31 to delete the  
alleged indefinite claim language. All of these amendments are  
supported by the specification as filed and none adds new  
matter.

Applicant has cancelled claim 32 to expedite allowance  
of the amended claims. Applicant expressly reserves the right  
to file divisional or continuing applications claiming priority  
from this application directed to the cancelled subject matter.

THE REJECTION UNDER 35 U.S.C. § 112, FIRST PARAGRAPH

The specification stands objected to, and claims 31-34  
stand rejected under 35 U.S.C. § 112, first paragraph, for